全面纵向细胞因子谱及其与不同免疫表型和结局的关联:一项静脉-静脉体外膜氧合的前瞻性临床研究
该前瞻性研究纳入35例接受VV ECMO的成年难治性呼吸衰竭患者,在ECMO启动前及启动后第1-4天、第7天和每周直至拔管纵向采集血样,用多重组珠基检测法测定48种细胞因子和趋化因子,并用ELISA检测多种酶。主成分分析和层次聚类识别出不同免疫表型。ECMO前TNF-B和RANTES升高与生存降低显著相关,而IFN-a2、IL-1Ra、IL-12p40、MCP-1、IL-8、MIP-1a、IL-1和SCF升高与不良事件减少相关(p<0.05);IFN-a2、IP-10、MCP-1、MIP-1a、SCF和DPP3与延长呼吸机依赖显著相关(p<0.05)。炎症标志物可能与VV ECMO临床终点相关,但需多中心研究验证。
要点
- 在35例成年难治性呼吸衰竭VV ECMO患者中,ECMO前TNF-B和RANTES浓度升高与生存降低显著相关(p<0.05)。
- ECMO前IFN-a2、IL-1Ra、IL-12p40、MCP-1、IL-8、MIP-1a、IL-1和SCF升高与不良事件减少显著相关(p<0.05)。
- IFN-a2、IP-10、MCP-1、MIP-1a、SCF和DPP3与延长呼吸机依赖显著相关(p<0.05)。
- 聚类分析在VV ECMO患者中识别出不同的免疫表型。
- 作者认为这是迄今最全面的VV ECMO细胞因子和趋化因子谱分析,采用ECMO前即刻采样和先进聚类技术,但需更大规模多中心研究验证。
适用人群与场景
- 35例接受VV ECMO的成年难治性呼吸衰竭患者,前瞻性纳入。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性临床研究;样本量:35例成年患者;中心数:原文未提及。
- 人群:接受VV ECMO的难治性呼吸衰竭成年患者。
- 干预/方法:ECMO启动前及启动后第1-4天、第7天和每周直至拔管纵向采集血样,用多重组珠基检测法测定48种细胞因子和趋化因子,用ELISA检测多种酶;主成分分析和层次聚类识别免疫表型;回归模型评估生物标志物、聚类与临床结局的关联。
- 关键次要终点:聚类分析揭示受试者中存在不同的免疫表型;具体聚类结果原文未提及。
- 不良事件:原文未提及具体不良事件数据。
证据类型、等级与局限
- 证据类型:前瞻性临床研究(单中心,原文未明确说明中心数,但样本量35例提示可能为单中心)。
- 证据等级或推荐强度:原文未提及。
- 局限:样本量小(35例);原文指出需更大规模多中心研究验证;原文未提及盲法、失访等细节。
对床旁实践的改变
- 原文提示ECMO前TNF-B和RANTES升高可能与生存降低相关,IFN-a2、IL-1Ra、IL-12p40、MCP-1、IL-8、MIP-1a、IL-1和SCF升高可能与不良事件减少相关,但作者明确需多中心研究验证,不能据此改变床旁决策。
- 原文未提及基于细胞因子谱的个体化VV ECMO管理推荐,适用与不适用人群、常见陷阱原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Venovenous extracorporeal membrane oxygenation (VV ECMO) is a life‑saving intervention commonly used for severe and refractory respiratory failure. However, patient management and outcomes in this setting remain challenging as well as difficult to predict. Inflammatory reaction, namely by assessing cytokine and chemokine blood levels, may provide prognostic information, but their role in VV ECMO has not been comprehensively characterized.
METHODS: We prospectively enrolled 35 adult patients receiving VV ECMO for refractory respiratory failure. Blood samples were collected immediately prior to ECMO initiation and longitudinally on Days 1-4, 7, and weekly until decannulation. Plasma concentrations of 48 cytokines and chemokines were measured using a multiplex bead‑based assay, along with several enzymes by enzyme-linked immunosorbent assay. Principal component analysis and hierarchical clustering were used to identify immunologic phenotypes. Associations between biomarker levels, clusters, and clinical outcomes were evaluated using regression models.
RESULTS: Elevated pre‑ECMO concentrations of TNF‑B and RANTES were significantly associated with reduced survival, while higher IFN-a2, IL-1Ra, IL-12p40, MCP-1, IL-8, MIP-1a, IL-1, and SCF were associated with fewer adverse events (p<0.05). Several cytokines, including IFN‑a2, IP‑10, MCP‑1, MIP‑1a, SCF, and DPP3, were significantly correlated with prolonged ventilator dependence (p<0.05). Cluster analysis revealed distinct immunologic phenotypes among subjects.
CONCLUSIONS: Inflammatory markers may be associated with clinically meaningful endpoints in VV ECMO, namely, survival, adverse events, and prolonged dependence on mechanical ventilation. To our knowledge, this study represents the most comprehensive cytokine and chemokine profiling in VV ECMO patients to date, using immediate pre‑ECMO sampling and advanced clustering techniques. Larger multicenter studies are warranted to validate these findings and explore their application in guiding individualized VV ECMO management and enhancing patient prognostication.
参考来源
- Hagiwara J, Liu Q, DellaVolpe JD, et al. Comprehensive Longitudinal Cytokine Profiling and their Associations with Distinct Immunologic Phenotypes and Outcomes: A Prospective Clinical Study in Venovenous ECMO. Shock. 2026. PMID: 42752598. doi:10.1097/SHK.0000000000002943
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。